Efficacy and safety of high and low dose recombinant human erythropoietin on neurodevelopment of premature infants
A meta-analysis

Na Qin, MD, Huibin Qin, MD*

Abstract

Background: To evaluate the effect of recombinant human erythropoietin (rhEPO) in nervous system of premature infants including different dosage.

Methods: The multiple databases like Pubmed, Embase, Cochrane databases and China National Knowledge Database were used to search for the relevant studies, and full-text articles involved in the evaluation on effect of rhEPO for neurodevelopment among premature infants. Review Manager 5.2 was adopted to estimate the effects of the results among selected articles. Forest plots, sensitivity analysis and bias analysis for the articles included were also conducted.

Results: Finally, 10 eligible studies were eventually satisfied the included criteria. The results showed that rhEPO was much higher than placebo group in composite cognitive score (MD = 5.89, 95% confidential interval [CI] [1.95, 9.82], P = .003; I² = 89%) and low dose rhEPO also had higher composite cognitive score than placebo group (MD = 10.39, 95% CI [8.84, 11.93], P < .0001, I² = 0%) and no difference in neurodevelopmental impairment between rhEPO and placebo was insignificant (RR = 0.95 95% CI [0.71, 1.29], P = .65). Composite cognitive score in high dose rhEPO was much higher than placebo group (MD = 2.58, 95% CI [0.80, 4.37], P = .004, I² = 11%). Limited publication bias was observed in this study.

Conclusion: Recombinant human erythropoietin might be a promotor for neurodevelopment among premature infants with limited adverse events.

Abbreviations: CI = confidential interval, EPO = erythropoietin, rhEPO = recombinant human erythropoietin.

Keywords: meta, neurodevelopment, premature infants, rhEPO

1. Introduction

In developed countries, premature babies accounted for 5% to 7% of live births. Due to economic factors, developing countries had a higher premature birth rate than developed countries. The risk of delayed nervous system development in preterm infants was significantly higher than that in term infants. Neurodevelopmental disorders (nervous system abnormalities including cerebral palsy, deafness, blindness and/or mental development index score <70) accounted for 36% to 48% of preterm infant survivors.[1,2] Studies had shown that the nursing progress of babies born before 28 weeks of pregnancy was related to a significant increase in survival. However, about 40% of infants born before 28 weeks would have one or more serious injuries (such as cerebral palsy, intellectual disability, deafness or blindness) and the increase would be higher after a few weeks.[3,4] Children were at higher risk of behavioral autism and mental disorders. There was an urgent need for neuroprotective agents to improve the prognosis of preterm infants.

Erythropoietin (EPO) was originally used to promote red blood cell production and treat anemia.[5] Animal experiments showed that erythropoietin and its receptors are expressed in the central nervous system, and that erythropoietin could pass through the blood-cerebrospinal fluid barrier of many animals to play a protective role in the nervous system. Various animal brain injury models such as hypoxic-ischemic brain injury, focal cerebral ischemia, traumatic injury of the brain and spinal cord, autoimmune cerebrospinal meningitis, showed that EPO treatment could reduce brain injury and improve nerve function.[6,7]

Although the prognosis of premature babies had improved in recent decades, they still experienced severe long-term neurodevelopmental delay.[8] Magnetic resonance imaging (MRI) showed that the underlying pathology was called premature encephalopathy. Among several drug candidates to prevent brain damage or promote brain development, erythropoietin (EPO)
had proven to be the most promising.\textsuperscript{[9,10]} Erythropoietin stimulated the proliferation, survival and differentiation of erythroid cells. Recent evidence indicated that EPO played a role in tissue development and protection, and EPO receptors were also expressed in other cell types such as endothelial cells, glial cells and neuronal cells.\textsuperscript{[11]} Animal experiments first proved the neuroprotective effect of EPO. The underlying mechanisms explaining this effect included inhibition of glutamate release, regulation of intracellular calcium metabolism, production of anti-apoptotic factors, and anti-inflammatory and antioxidant effects. Preclinical data supported the results of clinical trials to evaluate the neuroprotective effect of recombinant human erythropoietin (rhEPO) on term infants with hypoxic-ischemic encephalopathy. Retrospective recent studies using rhEPO had shown that EPO also improved the neurodevelopmental outcome of preterm infants.\textsuperscript{[12]} When passing through the blood-brain barrier, epo must be administered at a high dose of 2000 to 5000 IU/kg body weight. Premature infants tolerate these high doses well. Compared with reports several weeks after treatment, treatments sufficient to block brain receptors in a short period of time did not increase the risk of retinopathy in premature infants.\textsuperscript{[2]} According to reports, there was an association between early high-dose rhEPO and full-term brain MRI evaluation of very premature infants, and there was an association between the incidence of white and gray matter damage.\textsuperscript{[3]}

In recent years, the value of rhEPO in neurodevelopment among premature infants had been noted, but the detailed role of rhEPO had not been fully understood. Here, we conducted a meta-analysis to evaluate the effects of rhEPO in neurodevelopment among premature infants.

2. Methods

2.1. Literature search strategy

We searched articles published between January 2010 and March 2020 for rhEPO and placebo in premature infants neurodevelopment. Searchable databases included PubMed, EmBase, Cochrane database and China National Knowledge database, and use the following strategy: (neurodevelopment OR nerve\textsuperscript{*} OR neurological\textsuperscript{[8]} AND (recombinant human erythropoietin OR rhEPO) AND (dose OR different dose). There were no restrictions on the publication language in the literature search. In order to maximized the specificity and sensitivity of the search, the author should also check the reference list of research to seek other relevant research that was not found through the search strategy. Besides, an ethics committee or institutional review board approved the study.

2.2. Study selection

inclusion criteria and exclusion criteria

We used the following inclusion criteria for our research:

1. A study with RCT design;
2. A study to evaluate rhEPO and placebo in clinical effects and safety;
3. Containing data in different year;
4. Available in full text.

If the research meets one of the following conditions, it is excluded:

1. Overlapping data or overlapping review articles;
2. The included samples were not premature infants; and
3. Other articles design.

2.3. Data extraction and quality assessment

Two commentators independently scanned the full text of the manuscript and extracted the following data from each eligible study: first authors name, patient’s age and gender, country of origin, year of publication, sample size, study period of each article. Cochrane risk of bias assessment tool was used to evaluate the methodological quality of the study. Cochrane risk assessment tool was a comprehensive tool to consider multiple biases.

2.4. Statistical analysis

Review Manager (version 5.2, Cochrane Collaboration, 2011) was used to assess the impact of results in selected reports. For continuous results, the mean difference was calculated by the average difference. Heterogeneity in research $I^2$ Statistics, a quantitative measure of inconsistency in research. 25% to 50% of the studies with $I^2$ were considered as low heterogeneity, 50% to 75% of the studies with $I^2$ were considered as medium heterogeneity, and 75% of the studies with $I^2$ were considered as high heterogeneity. If $I^2 > 50\%$, the potential sources of heterogeneity were examined by sensitivity analysis, which omits 1 study in each round and investigates the impact of a single study on portfolio estimation. In addition, when heterogeneity was observed, the random effect model was used, and when it does not exist, the fixed effect model was used. Funnel charts, Begger test and Egger test were used to check for potential publication bias.

Since our research is a meta-analysis, all the data were extracted from published articles, ethical review was unnecessary.

3. Results

3.1. Search process

The electronic search ended with 401 articles. After careful reading, 98 papers had reached the preliminary standard. In the further screening, 88 articles were excluded because of improper research type and insufficient data and article type. Finally, 10 papers were selected for analysis. Figure 1 was a flowchart of identification, inclusion, and exclusion, reflecting the search process and the reason for exclusion.

3.2. Characteristics of included studies

Detailed characteristics of the included studies were presented in Table 1.\textsuperscript{[13–22]} All these studies were published from 2010 to 2020. The sample size ranged from 53 to 1285. Totally 2368 patients were in rhEPO group, and 2265 patients were in placebo group.

3.3. Results of quality assessment

The Cochrane risk of bias assessment tool was used to evaluate the risk of patient selection problems in 10 trials. None showed the problem of bias. In view of the bias summary, there was no problem in selection bias, performance bias, detection bias, attrition bias and reporting bias. In general, 10 included trials had no risk of bias.
Figure 1. Flow diagram of the study selection.

Table 1
Characteristics of studies included in the meta-analysis.

| Study     | Year | Language | Country   | cumulative dose of Erythropoietin | Gestational age (weeks) | Groups       | n   | Years of onset                        |
|-----------|------|----------|-----------|-----------------------------------|-------------------------|--------------|-----|---------------------------------------|
| Fauchere  | 2015 | English  | Switzerland | 3000 U/kg                          | 29±1.1                  | rhEPO        | 229 | September 2005 to December 2012       |
| Juul      | 2020 | English  | America    | 6000 U/kg                          | 29±1.2                  | Placebo      | 214 | December 2013 to September 2016       |
| Leuchter  | 2014 | English  | Switzerland | 3000 U/kg                          | 29.1±6.2               | rhEPO        | 476 | 2005 to 2012                          |
| Luciano   | 2015 | English  | Italy      | 6300 U/kg                          | 29.1±6.2               | Placebo      | 239 | 2005 to 2012                          |
| Natalucci | 2016 | English  | Switzerland | 3000 U/kg                          | 29.1±6.2               | rhEPO        | 59 | December 2004 to January 2007        |
| Neubauer  | 2010 | English  | Germany    | 8574 U/kg                          | 29.1±6.2               | Placebo      | 45 | 2005 to 2012                          |
| Ohls      | 2014 | English  | America    | 1200 U/kg                          | 27.1±1.9               | rhEPO        | 89  | January 1993 to December 1998        |
| Qiao      | 2017 | English  | China      | 1600 U/kg                          | 27.8±1.9               | Placebo      | 29  | 2008 to 2012                          |
| Song      | 2016 | English  | China      | 3500 U/kg                          | 30.3±2.1               | Placebo      | 31  | February 2014 to June 2014            |
| Wang      | 2020 | English  | China      | 3500 U/kg                          | 30.4±1.3              | rhEPO        | 366 | January 2009 to June 2013            |
|           |      |          |            |                                   | 29.7±1.5              | Placebo      | 377 | January 2014 to June 2017            |

Qin and Qin Medicine (2021) 100:18 www.md-journal.com
3.4. Results of meta-analysis

3.4.1. Meta-analysis about composite cognitive score among premature infants. As shown in Figure 4, 7 included studies involved in composite cognitive score, and there was significant difference between rhEPO and placebo in composite cognitive score. Since $I^2 = 89\%$, random effects model was adopted. The result showed that rhEPO was much higher than placebo group in composite cognitive score (MD = 5.89, 95% confidential interval [CI] [1.95, 9.82], $P = .003$; $I^2 = 89\%$, Fig 4).

3.4.2. Meta-analysis about death among premature infants. Three included studies were involved in death between rhEPO and placebo. As shown in the forest plot (Fig. 5), and since $I^2 = 51\%$, random effects model was adopted. The result of meta-analysis showed that there was no significant difference between rhEPO and placebo groups (RR = 0.93, 95% CI [0.60, 1.43], $P = .74$; $I^2 = 51\%$).

3.4.3. Meta-analysis about neurodevelopmental impairment among premature infants. In the analysis, 2 articles were included. The results of heterogeneity test showed that random effect model was needed to analyze the data ($I^2 = 74\%$). The overall difference of neurodevelopmental impairment between rhEPO and placebo was insignificant (Fig. 6, RR = 0.55 95% CI [0.30, 1.02], $P = .06$).

3.4.4. Meta-analysis about subgroup in composite cognitive score. As shown in Figure 7, 3 included studies were involved in high dose rhEPO, and 4 articles were selected in low dose rhEPO. Since $I^2 = 0\%$, fixed effects model was adopted. The result showed that composite cognitive score in high dose rhEPO was much higher than placebo group (MD = 10.39, 95% CI [8.84, 11.93], $P < .0001$, $I^2 = 0\%$, fig. 7) and low dose rhEPO also had higher composite cognitive score than placebo group (MD = 2.58, 95% CI [0.80, 4.37], $P = .004$, $I^2 = 11\%$, fig. 7).

3.5. Results of sensitivity analysis and publication bias

According to meta-analysis, the heterogeneity of composite cognitive score was low ($I^2 = 89\%$). As shown in Figure 8 the heterogeneity of composite cognitive score might be attributed to the different results of each study. When the article of July in 2020 was excluded, $I^2$ changed to 41%. This indicated that the result in this article was robust.

A funnel plot for composite cognitive score was performed. Seven studies were included in the plot. The result indicated that
there existed limited publication bias since the symmetrical characteristic of the funnel plot is fine, which showed there exist no publication bias in this analysis (Fig. 9). The result of Begger test also suggested that no significant evidence of potential publication bias existed ($z = 1.25, P = .131$) and Egger test also suggested that no significant evidence of potential publication bias existed ($t = 1.21, P = .225$).

4. Discussion

The results showed that rhEPO was much higher than placebo group in composite cognitive score, which indicated that rhEPO might have the clinical benefits of neurodevelopment. Rao stated that early application of rhEPO can protect the nervous system of preterm infants, and the effect of low-dose application is more effective.[5] However, a number of multicenter randomized controlled clinical studies are needed to further confirm the effects of rhEPO. Our results showed that the differences in death and neurodevelopment between rhEPO and placebo had no significance. In the further analysis, we divided samples into 2 subgroups based on dosage of rhEPO. Compared with Zhang’s report[6] that the effect of low-dose application was more effective than high-dose, the results showed that both rhEPO in high dose and low dose had higher composite cognitive score than placebo group. This was may be caused by different included indicators, and in his article, neonatal behavior neuro-developmental assessment (NBNA), mental development index (MDI), and psychomotor development index (PDI) were analyzed.

Brain damage in premature infants could cover various diseases such as hypoxic-ischemic brain injury, cerebral hemorrhage, hydrocephalus, periventricular white matter softening, etc. Children manifested with cerebral palsy and neurodevelopmental...
disorders, which could affect movement, behavior, and cognition. In this respect, it seriously affected the quality of life of the children and brings a heavy burden to the family and society.\textsuperscript{[23]}

The current treatment methods for this disease mainly include mild hypothermia therapy, scavenging free radicals to protect damaged cells, and hormones but the effects are not satisfactory.\textsuperscript{[24]} Studies have pointed out that premature stimulation and overtraining of premature infants can have an adverse effect on the central nervous system.\textsuperscript{[24,25]} Therefore, for premature babies, especially those with brain damage, it was difficult to conduct interventional training before correcting the gestational age of 40 weeks. In recent years, early intervention for premature infants with brain injury to improve the quality of life and reduce the occurrence of sequelae had become the focus of neonatal medical research.

Premature babies were often immature, and the immaturity of the nervous system and its complications had an important influence on the long-term development of premature babies. Numerous experiments and retrospective clinical studies had shown that EPO had a similar effect as a neuroprotective factor, and its mechanism might deal with these 2 processes at the same time.\textsuperscript{[26]} EPO inhibited the release of glutamate, regulates intracellular calcium metabolism, and induces neuronal apoptosis. Mechanisms might include death factors, reduction of inflammation, reduction of NO-mediated damage, and direct anti-oxidation to prevent acute injury. On the other hand, EPO affected its developmental mechanism by promoting the proliferation and differentiation of preoligodendrocytes, then it stimulated growth factors and inhibited nerve cell apoptosis.\textsuperscript{[27]}

EPO was essentially a glycoprotein, which was secreted and released by the kidneys, but it was also expressed in small amounts in brain and other tissues. It was named for its effective function of promoting bone marrow hematopoiesis. It was used in the treatment of renal anemia in the early stage. With the deepening of research, researchers found that it had a certain repair effect on the damage of the nervous system, and could protect the nerve by inhibiting the degradation of nerve cell protein and activating the function of mitochondria.\textsuperscript{[26,27]}

---

**Figure 7.** Forest plots of subgroup in composite cognitive score between rhEPO and placebo among premature infants.

**Figure 8.** Sensitivity analysis of composite cognitive score between rhEPO and placebo among premature infants.
In conclusion, recombinant human erythropoietin might be a promoter for neurodevelopment among premature infants with limited adverse events. Besides, some limitations existed in this article. Firstly, the comparison in different areas was not considered, which could be evaluated in the further research. Secondly, the details about complications were not included, and details could be evaluated in the future.

**Author contributions**

Conceptualization: Na Qin.
Data curation: Huibin Qin, Na Qin.
Formal analysis: Huibin Qin.
Methodology: Na Qin.
Resources: Na Qin.

**References**

[1] Obladen M, Diepold K, Maier RF. Venous and arterial hematologic profiles of very low birth weight infants. European Multicenter rhEPO Study Group. Pediatrics 2000;106:707–11.
[2] Jiang GM, Chen YB. Preventive effect of recombinant human erythropoietin for necrotizing enterocolitis of premature infants. Chin J Neonatol 2010;11:118–25.
[3] Benoist . Olfaction in the fetal and premature infant: functional status and clinical implications. Clin Perinatol 2004;31:44–53.
[4] Schaal B, Hummel T, Soussignan R. Olfaction in the fetal and premature infant: functional status and clinical implications. Clin Perinatol 2004;31:261–85.
[5] Rao SQ. Efficacy of early erythropoietin and iron use in very-low-birth-weight premature infants. J Neonatol 2005;52:103–12.
[6] Zhang GR. Effect and of rhEPO in the treatment of anemia in premature infants: a meta-analysis. Chin J Birth Health Heredity 2013;78:45–52.
[7] Messer J. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics 2010;7:24–124.
[8] Liao JH, Song YY, Li S. Clinical observation of recombinant erythropoietin in early prevention and treatment of brain injury in preterm infants. J China Prescription Drug 2014;98:1102–9.
[9] Lian Z. Different doses of erythropoietin protect neural development in premature infant. Stroke Nervous Diseases 2016;50:99–104.
[10] Melo A. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-alpha following single-dose subcutaneous administration in premature newborns. J Matern Fetal Neonatal Med 2005;17:55–8.
[11] Horng P, et al. Behavior of organic liquids at bare and modified silica interfaces. J Phys Chem C 2010;112:87–93.
[12] Chen Z. Application of recombinant human erythropoietin in the treatment of premature infant brain injury. Genomics Appl Biol 2017;89:121–9.
[13] Jean-Claude Fauchère KBMT. Safety of Early High-Dose Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants. J Pediatr 2015;18:52–7.
[14] Juul SE. A randomized trial of erythropoietin for neuroprotection in preterm infants. N Engl J Med 2020;382:233–43.
[15] Leuchter RH. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA 2014;312:817–21.
[16] Luciano R. Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report. Ital J Pediatr 2015;41:88–96.
[17] Nataf Z. Effect of early prophylactic high-dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years. JAMA 2079;315:108–15.
[18] Neubauer A, et al. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol 2010;NA-NA.
[19] Ohls RK, KBDC. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics 2014;13:1023–35.
[20] Qiao L. Effects of early parenteral iron combined erythropoietin in preterm infants. Medicine 2017;96:e5795–9.
[21] Juan Song HSFX. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol 2016;30:24–34.
[22] Wang Y. Erythropoietin prevents necrotizing enterocolitis in very preterm infants: a randomized controlled trial. Journal of Translational Medicine 2020;76:118–24.
[23] Hee . Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy: a pilot study. Brain Dev 2014.
[24] Kumral A. Protective effects of erythropoietin against ethanol-induced apoptotic neurodegeneration and oxidative stress in the developing C57BL/6 mouse brain. Brain Res Dev Brain Res 2005;160:146–56.
[25] Lee HS. Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy: A pilot study. Brain Dev 2014;36:764–9.
[26] Min K. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells 2013;31:581–91.
[27] Sifringer M. Erythropoietin attenuates hyperoxia-induced cell death by modulation of inflammatory mediators and matrix metalloproteinases. Developmental Neuroence 2009;31:394–402.